Literature DB >> 12433714

Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study.

Merethe Kumle1, Elisabete Weiderpass, Tonje Braaten, Ingemar Persson, Hans-Olov Adami, Eiliv Lund.   

Abstract

Current use of oral contraceptives (OCs) has been reported to increase breast cancer risk slightly. In 1991/1992, a prospective cohort study specifically designed to examine the role of hormonal contraceptives in relation to breast cancer was conducted in Norway and Sweden. This study was entitled Women's Lifestyle and Health. Of 196,000 invited women aged 30-49 years, 106,844 women answered a 4-page questionnaire. Altogether, 103,027 women providing information on contraceptive use were included in the analysis presented here, and 1,008 primary invasive breast cancers were diagnosed throughout 1999 (end of follow-up). Proportional hazard regression was used to calculate relative risks (RRs) with adjustment for age and other possible confounders. An increased breast cancer risk was observed among women who were current/recent users of OCs of any type at the start of follow-up [RR, 1.6; 96% confidence interval (CI), 1.2-2.1]. Current/recent use (i.e., use in the year preceding cohort enrolment) of combined OCs (RR, 1.5; 95% CI, 1.0-2.0) and progestin-only pills (RR, 1.6; 95% CI, 1.0-2.4) entailed similar levels of increased risk. An increased risk of borderline significance was found among short-term (i.e., less than 13 months) users before age 20 years (RR, 1.3; 95% CI, 1.0-1.7) and before first full-term pregnancy (RR, 1.4; 95% CI, 1.0-1.8). Long-term users of OCs were at a higher risk of breast cancer than never users (test for trend, P = 0.005). Current/recent use of OCs is associated with an increased breast cancer risk. Use of combined OCs and progestin-only pills seem to increase the risk at the same level.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12433714

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  53 in total

1.  AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.

Authors:  Christoph Thomssen; Anton Scharl; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2011-08-30       Impact factor: 2.860

2.  Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women.

Authors:  Lynn Rosenberg; Deborah A Boggs; Lauren A Wise; Lucile L Adams-Campbell; Julie R Palmer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

3.  Carotenoid intakes and risk of breast cancer defined by estrogen receptor and progesterone receptor status: a pooled analysis of 18 prospective cohort studies.

Authors:  Xuehong Zhang; Donna Spiegelman; Laura Baglietto; Leslie Bernstein; Deborah A Boggs; Piet A van den Brandt; Julie E Buring; Susan M Gapstur; Graham G Giles; Edward Giovannucci; Gary Goodman; Susan E Hankinson; Kathy J Helzlsouer; Pamela L Horn-Ross; Manami Inoue; Seungyoun Jung; Polyna Khudyakov; Susanna C Larsson; Marie Lof; Marjorie L McCullough; Anthony B Miller; Marian L Neuhouser; Julie R Palmer; Yikyung Park; Kim Robien; Thomas E Rohan; Julie A Ross; Leo J Schouten; James M Shikany; Shoichiro Tsugane; Kala Visvanathan; Elisabete Weiderpass; Alicja Wolk; Walter C Willett; Shumin M Zhang; Regina G Ziegler; Stephanie A Smith-Warner
Journal:  Am J Clin Nutr       Date:  2012-01-25       Impact factor: 7.045

4.  Hormonal contraception--what kind, when, and for whom?

Authors:  Inka Wiegratz; Christian J Thaler
Journal:  Dtsch Arztebl Int       Date:  2011-07-18       Impact factor: 5.594

5.  Prospective study of coffee consumption and all-cause, cancer, and cardiovascular mortality in Swedish women.

Authors:  Marie Löf; Sven Sandin; Li Yin; Hans-Olov Adami; Elisabete Weiderpass
Journal:  Eur J Epidemiol       Date:  2015-06-16       Impact factor: 8.082

6.  The chemopreventive effect of mifepristone on mammary tumorigenesis is associated with an anti-invasive and anti-inflammatory gene signature.

Authors:  Hongyan Yuan; Geeta Upadhyay; Jin Lu; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Prev Res (Phila)       Date:  2012-03-16

7.  Oral contraceptives and breast cancer risk overall and by molecular subtype among young women.

Authors:  Elisabeth F Beaber; Kathleen E Malone; Mei-Tzu Chen Tang; William E Barlow; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-14       Impact factor: 4.254

8.  A case-control study of oral contraceptive use and incident breast cancer.

Authors:  Lynn Rosenberg; Yuqing Zhang; Patricia F Coogan; Brian L Strom; Julie R Palmer
Journal:  Am J Epidemiol       Date:  2008-12-13       Impact factor: 4.897

9.  Effects of prior oral contraceptive use and soy isoflavonoids on estrogen-metabolizing cytochrome P450 enzymes.

Authors:  L M Scott; P Durant; S Leone-Kabler; C E Wood; T C Register; A Townsend; J M Cline
Journal:  J Steroid Biochem Mol Biol       Date:  2008-10-08       Impact factor: 4.292

10.  Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33,000 women from the general population.

Authors:  Maria Hedelin; Marie Löf; Marita Olsson; Tommy Lewander; Björn Nilsson; Christina M Hultman; Elisabete Weiderpass
Journal:  BMC Psychiatry       Date:  2010-05-26       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.